These activated CCR6+ILC3s can secrete CXCL10 that promotes CD4+ and CD8+ T cells migration to the tumor, enhancing anti-tumor immunity and response to immune checkpoint blockade (Figure 2). This evidence concerns the gene CD8A and neoplasm.